Background {#Sec1}
==========

Lupus is a chronic autoimmune disease that frequently involves the kidney. Lupus nephritis can lead to kidney failure, dialysis, and even premature death if not treated appropriately. Lupus primarily affects young women and is more common and more severe in racial/ethnic minorities, who experience worse outcomes \[[@CR1]--[@CR5]\].

Comparative effectiveness research (CER) of drugs used to treat lupus nephritis is an imperative \[[@CR6]\]. Patients, facing difficult decisions related to their treatment options, such as those related to life- and/or organ-threatening clinical situations (active lupus nephritis, for example) need information about possible harms and benefits of available treatment options in a format that provides comparisons of multiple treatment options.

The 2012 American College of Rheumatology (ACR) lupus nephritis treatment guidelines \[[@CR7]\] and the Cochrane systematic review of interventions for lupus nephritis \[[@CR8]\] assessed literature up to 2010 and 2012, respectively. However, indirect comparisons were not performed in either. Few lupus nephritis treatments have been compared directly in clinical trials. This leaves a large knowledge gap. Clinicians and patients have to choose between various immunosuppressive drugs in the absence of such knowledge. Therefore, we need evidence synthesis using valid methods to incorporate indirect and direct comparisons of efficacy/harms of these treatments.

A state-of-the-art network meta-analysis (NMA), with updated information, is a necessary precursor to the development of a clinical decision-making tool for physician and their patients with lupus nephritis. This information can be very helpful to patients during the treatment decision-making process for new disease, disease flare or refractory disease. It is not surprising that for a rare condition such as lupus with roughly 161,000 patients in the USA \[[@CR9]\], most multicenter trials have \<500 patients (often 50--200 patients). This makes many trials underpowered for assessing treatment-related differences in disease outcomes.

One useful approach is the use of composite outcomes, which have been widely used to address important clinical questions in obstetrics, cardiology, and other disciplines \[[@CR10]--[@CR12]\]. Assessments of treatment options using composite outcomes can help answer important question in a timely fashion without requiring studies with large sample sizes. This study aimed to perform a systematic review and NMA to compare benefits and harms of immunosuppressive drugs compared to each other and to corticosteroids focusing on four composite benefit/harm outcomes: (1) renal remission/response; (2) renal relapse/flare; (3) ovarian failure/amenorrhea; and (4) bone marrow toxicity.

Methods {#Sec2}
=======

We used rigorous methods for the systematic review and NMA based on the Agency for Healthcare Research and Quality (AHRQ) recommendations \[[@CR13]\], the Cochrane handbook \[[@CR14]\], and the PRISMA guidelines. The Institutional Review Board at the University of Alabama at Birmingham (UAB) approved the study. The need for informed consent was waived for this systematic review, since no human subjects were involved. The study protocol was registered in PROSPERO, CRD42016032965 (<http://www.crd.york.ac.uk/PROSPERO/>).

Methods for systematic review: study eligibility criteria, outcomes and data abstraction {#Sec3}
----------------------------------------------------------------------------------------

This systematic review included randomized controlled trials (RCTs) or controlled clinical trials (CCTs) of immunosuppressive drugs or corticosteroids for lupus nephritis, published in English that reported any safety or efficacy outcome. Included medications were: corticosteroids \[PRED\]; cyclophosphamide \[CYC\]; mycophenolate mofetil \[MMF\]; azathioprine \[AZA\]; cyclosporine \[CSA\]; tacrolimus \[TAC\]; or rituximab \[RTX\], Belimumab studies could not be included in this systematic review since these studies included patients with lupus, and only a small proportion had active lupus nephritis. A Cochrane systematic review of belimumab for lupus in underway \[[@CR15]\]. There were no restrictions with regards to the medication dose or the duration of medication use.

Experienced librarians (JJ and TR) updated two systematic reviews \[[@CR7], [@CR8]\] from their search end dates (August 2010 and April 2012, respectively) to September 2013 using the PubMed database. The search used the following terms: (Lupus\[text word\] OR \"Lupus Vulgaris\"\[MeSH\] OR \"Lupus Erythematosus, Cutaneous\"\[MeSH\] OR \"Lupus Erythematosus, Systemic\"\[Mesh\]) AND (\"Kidney Diseases\"\[MeSH\] OR nephropath\*\[text word\] OR Transplants\[MeSH\] OR Transplantation\[MesH\] OR transplantation\[subheading\] OR transplant\*\[text word\] OR \"Kidney\"\[Mesh\] OR Kidney\*\[text word\] OR Renal\*\[text word\] OR \"End Stage Renal Disease\"\[text word\] OR ESRD\[text word\] OR Glomerulonephr\*\[text word\] OR \"GN\"\[text word\] OR \"crescentic GN\"\[text word\]) NOT (\"animals\"\[MeSH\] NOT \"humans\"\[MeSH\]).

Raw data abstracted for the ACR lupus nephritis guidelines systematic review \[[@CR7]\] were obtained (courtesy Dr. Jennifer Grossman (JG), see acknowledgment section), or were abstracted from the Revman tables of the Cochrane Systematic Review \[[@CR8]\]. A librarian (CH) also performed a search for all lupus trials for harms (for conditions other than lupus nephritis) in PubMed and SCOPUS from inception to February 2014, based on an a priori assumption that treatment-related harms may not depend on whether kidney is involved or not. Examination of data from this search revealed little additive data for harms, but added clinical heterogeneity related to differences in patient population. Therefore, after careful consideration of pros and cons, we decided not to use these data in analyses.

The PICO (patient, intervention, comparator, outcome) for our systematic review and NMA were defined as follows:"P: Adults 18 years or older, meeting the 1987 American College of Rheumatology Classification criteria for systemic lupus erythematosus (SLE) \[[@CR16]\], who have lupus nephritis.I: Immunosuppressant drug alone or in combination with other immunosuppressant drugs or biologics (such as rituximab) or corticosteroids. Medication doses were categorized as low, standard or high dose/duration (LD, SD and HD).C: Placebo or another immunosuppressive with/without biologic.O: Benefit and harm outcomes (renal remission/response, renal relapse/flare, fertility, bone marrow suppression), defined as follows."

Benefits were assessed by two composite outcomes (for detailed definitions of components, see Additional file [1](#MOESM1){ref-type="media"}): (1) renal remission/response (indicating success of therapy): included complete renal remission, \[[@CR17]\] partial renal remission \[[@CR18], [@CR19]\] and renal response; (2) renal relapse/flare (indicating failure of therapy): included renal relapse \[[@CR20]\] and renal flare (Additional file [1](#MOESM1){ref-type="media"}). Harms were assessed by two composite outcomes: (1) ovarian failure/amenorrhea: included ovarian failure and amenorrhea; and (2) bone marrow toxicity: cytopenia including leucopenia.

Two trained abstractors (AO, AB) independently reviewed abstracts and titles, abstracted data in duplicate directly into Microsoft excel sheets and assessed the risk of bias according to the Cochrane risk of bias tool \[[@CR21]\]. We examined the following domains as low or high risk of bias or unclear risk (lack of information or uncertainty about potential for bias): randomization sequence generation, allocation sequence concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data (primary outcome data reporting, dropout rates and reasons for withdrawal, appropriate imputation of missing data, an overall completion rate ≥80 %), and selective outcome reporting and other potential threats to validity (considering external validity, e.g., relevant use of co-interventions, bias due to funding source). An adjudicator (JS) resolved any disagreements not resolved by consensus. An expert rheumatologist (JS) and an expert in lupus (JG) examined for similarity of studies prior to performing evidence synthesis by the examination of similarity of study population and interventions.

We designated doses as follows: (1) CYC: standard-dose/duration , SD: 0.5--1.0 gm/m^2^ intravenously (IV) q month for 6--12 months or 2--2.5 mg/kg orally (PO) daily × 3--6 months; high-dose/duration, HD: dose higher or duration longer than SD; low-dose/duration, LD: lower dose or duration shorter than SD, including the EURO-lupus dose, 500 mg IV q14 days × 6 doses (mean 3 g); (2) AZA: SD, 1--3 mg/kg po daily; HD, \>3 mg/kg po daily; (3) LEF: 1 mg/kg po qd × 3 days then 30 mg po qd x 6 months; and (4) PRED: SD, prednisone/methylprednisolone 1 gm/m^2^ IV q month × 6 months or prednisone 60 mg po qd 1--3 months then tapered over 3--12 months as tolerated; HD, prednisone/methylprednisolone 1gm/m^2^ qd IV × 3, then one dose q month for 1 year or prednisone 1 mg/kg daily for 4--8 weeks (or unspecified period). When dose is not specified, medication dose is the standard dose.

Bayesian network meta-analysis (NMA) {#Sec4}
------------------------------------

We used Bayesian mixed treatment comparison (MTC) meta-analyses \[[@CR22]--[@CR24]\] to assess the comparative effectiveness of one immunosuppressive drug vs. another and immunosuppressive drugs vs. corticosteroids. Bayesian MTC meta-analysis using a binomial likelihood model was conducted using WinBUGS software (MRC Biostatistics Unit, Cambridge, UK) which allows inclusion of data from multi-arm trials \[[@CR25], [@CR26]\] We conduced random-effects NMA and assessed model fit and the choice of model (random vs. fixed effects) based on the assessment of the deviance information criterion (DIC) and the comparison of residual deviance to the number of unconstrained data points \[[@CR25], [@CR27]\].

We assigned vague priors, such as N(0, 100^2^) for basic parameters throughout \[[@CR25]\] and informative priors for the variance parameter based on Turner et al. \[[@CR28]\]. We evaluated the model diagnostics including trace plots and the Brooks-Gelman-Rubin statistic to ensure model convergence \[[@CR25], [@CR29]\]. We fit three chains in WinBUGS for each analysis, with 40,000 iterations, and a burn-in of 40,000 iterations \[[@CR29], [@CR30]\] Both MTC and traditional meta-analysis require studies to be sufficiently similar in order to pool their results. We investigated heterogeneity, where warranted, with subgroup analyses and meta-regressions \[[@CR26], [@CR31]\]. We examined consistency-inconsistency plots for evidence of inconsistency, and chose the appropriate model for our analyses. We obtained point estimates using odds ratios (OR) and 95 % credible intervals (CrI) using Markov Chain Monte Carlo (MCMC) methods. Transformation of the OR to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients. The quality of evidence was assessed as recommended in a recent study \[[@CR32]\].

Sensitivity analysis was performed by limiting analyses to partial/complete remission rather than combining this with renal response for the composite renal remission/response. We constructed staircase diagrams, another pictorial way to see comparisons of various treatments to each other. Rankograms were constructed to model the probabilities of the treatment rankings, representing the best to the last ranks.

Results {#Sec5}
=======

Study characteristics {#Sec6}
---------------------

Sixty-five studies met inclusion and exclusion criteria that included CYC, MMF, AZA, calcineurin inhibitors (cyclosporine, tacrolimus), rituximab, corticosteroids, plasmapharesis, or leflunomide (Fig. [1](#Fig1){ref-type="fig"}). The Additional file [2](#MOESM2){ref-type="media"} shows the search strategy. An additional file shows the PRISMA checklist (see Additional file [3](#MOESM3){ref-type="media"}).Fig. 1PRISMA study flow chart for study selection. Legend: none

Network diagrams for all outcomes are shown in Fig. [2](#Fig2){ref-type="fig"}. Most studies (88 %) compared induction or induction and maintenance regimens. An additional file shows this in more detail (see Additional file [4](#MOESM4){ref-type="media"}). The study sample size ranged from 10 to 370. Of these, 32 % of the studies were conducted in the USA and 43 % were multicenter.Fig. 2Network diagrams for composite study outcomes in lupus nephritis, renal remission or renal response (**a**), renal relapse or renal flare (**b**), fertility issues (**c**), and bone marrow toxicity (**d**). Legend: Each *node* shows the treatment compared along with the number of RCTs that provide evidence. The size of each node is proportional to the sample size. **a** shows only the direct evidence, while **b**--**d** show both direct and indirect evidence. Direct evidence is indicated by *lines* indicating the number of RCTs providing the evidence and indirect by *lines* without this information. This was done since there were several direct comparator studies available for **a**, and addition of connections based on indirect evidence to **a** would make the network diagram very complex and difficult to visualize and understand

A detailed risk of bias using the Cochrane risk of bias tool is provided in Table [1](#Tab1){ref-type="table"}. Randomization was low-risk in 56 %, unclear in 39 % and high-risk in 5 % (Table [1](#Tab1){ref-type="table"}). Most trials were low-risk for blinding of assessor (59 %), blinding of participant (54 %), intention to treat (57 %). On the other hand, only 38 % of trials were low-risk for allocation concealment and it was unclear in 59 %. Although some clinical heterogeneity was detected between trials overall, we did not notice any clinically significant systematic differences in patient populations or disease stages between various medications.Table 1Risk of bias of included studies according to the Cochrane Risk of Bias tool^a^AuthorYearRandomizationAllocation concealmentBlinding of assessor and/or physician (for assessment of objective outcomes)Blinding of participants (for assessment of subjective outcomes)Intention to treatFree of selective reportingSource of fundingAustin2009Low riskLow riskHigh riskHigh riskUnclear riskUnclear riskUnclear riskCarette1983Unclear riskUnclear riskHigh riskHigh riskLow riskHigh riskLow riskSteinberg1991Low riskLow riskLow riskLow riskLow riskUnclear riskUnclear riskDonadio1976Unclear riskUnclear riskHigh riskHigh riskLow riskUnclear riskLow riskPohl1991Unclear riskUnclear riskHigh riskHigh riskUnclear riskUnclear riskUnclear riskWang2007Unclear riskUnclear riskHigh riskHigh riskHigh riskUnclear riskUnclear riskIsenberg; An analysis of ALMS study2010Low riskLow riskLow riskUnclear riskLow riskLow riskUnclear riskAppel (ALMS study)2009Low riskLow riskLow riskUnclear riskLow riskLow riskUnclear riskAustin1986Low riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskBalletta1992Unclear riskUnclear riskLow riskLow riskLow riskUnclear riskLow riskBao2008Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskBarron1982High riskHigh riskLow riskLow riskHigh riskHigh riskLow riskBoumpas1992Unclear riskLow riskLow riskLow riskLow riskLow riskUnclear riskCade1973High riskUnclear riskLow riskLow riskUnclear riskUnclear riskUnclear riskChan2000Low riskUnclear riskLow riskLow riskLow riskLow riskUnclear riskChen2011Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskClark1981Unclear riskUnclear riskLow riskLow riskLow riskLow riskLow riskClark1984Unclear riskUnclear riskLow riskLow riskUnclear riskUnclear riskUnclear riskContreras2002Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskCYCLOFA-LUNE Study2010Low riskLow riskLow riskLow riskLow riskLow riskLow riskDerksen1988Low riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskDonadio1974Low riskUnclear riskLow riskLow riskUnclear riskHigh riskLow riskDonadio1978Low riskUnclear riskLow riskLow riskUnclear riskUnclear riskUnclear riskDoria1994Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskDyadyk2001Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskEl-Shafey2010Low riskUnclear riskLow riskLow riskLow riskLow riskLow riskFu1998Low riskLow riskLow riskLow riskLow riskHigh riskLow riskGinzler2005Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskGourley1996Low riskLow riskLow riskLow riskLow riskLow riskLow riskGrootscholten (Dutch Lupus study)2006Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskHahn1975Low riskLow riskLow riskLow riskLow riskLow riskLow riskHong2007Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskHoussiau2002Low riskUnclear riskLow riskLow riskLow riskLow riskLow riskLewis1992Low riskUnclear riskLow riskLow riskLow riskLow riskLow riskLi2009aLow riskLow riskLow riskLow riskLow riskLow riskUnclear riskLi2009bUnclear riskUnclear riskLow riskLow riskLow riskLow riskLow riskLui1997Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskLUNAR Study2012Low riskUnclear riskLow riskLow riskLow riskLow riskUnclear riskMAINTAIN Nephritis Study2010Low riskUnclear riskLow riskLow riskLow riskLow riskLow riskMitwalli2011Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskMok2009Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskMoroni2004Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskMulic-Basic2008Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskMy-Lupus Study2010Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskOng2005Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskSabry2009High riskHigh riskLow riskLow riskLow riskLow riskLow riskSesso1994Unclear riskUnclear riskHigh riskLow riskLow riskUnclear riskLow riskSteinberg1971Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskSundel/Sandel2008Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskWallace1998Unclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskUnclear riskYee2004Low riskUnclear riskLow riskLow riskLow riskHigh riskLow riskLi2012Unclear riskUnclear riskHigh riskHigh riskHigh riskUnclear riskLow riskYap2012Unclear riskUnclear riskHigh riskHigh riskHigh riskUnclear riskUnclear riskStoenoiu2012Unclear riskUnclear riskUnclear riskUnclear riskHigh riskUnclear riskUnclear riskChen2012Low riskLow riskHigh riskHigh riskHigh riskUnclear riskUnclear riskArends (long term FU of Dutch Lupus study)2012Low riskLow riskLow riskLow riskLow riskLow riskUnclear riskSundel (report of induction and maintenance phases of ALMS study)2012Low riskLow riskLow riskUnclear riskLow riskLow riskUnclear riskWalsh (post-hoc subgroup analysis of ALMS)2013Low riskLow riskLow riskUnclear riskLow riskLow riskUnclear riskPetrI2010Low riskUnclearHigh riskHigh riskLow riskUnclear riskLow riskZeher2011Low riskLow riskHigh riskHigh riskHigh riskUnclear riskHigh riskDooley2011Unclear riskUnclear riskUnclear riskUnclear riskHigh riskUnclear riskHigh riskRadhakrishnan 2010 was a pooled analyses of two studies, and Mok 2001, Hu 2002, and Wang 2008 \[[@CR33]--[@CR36]\] were observational studies used in the Cochrane Review; therefore, risk of bias could not be assessed for these studies^a^Higgins JP, Altman DG, Sterne JA. Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from <http://handbook.cochrane.org/>. In: Higgins JP, Green S, eds 2011

Treatment efficacy: complete/partial renal remission/response {#Sec7}
-------------------------------------------------------------

Thirty-seven trials with 2697 patients provided data for the composite outcome, partial or complete renal remission or renal response (two trials were excluded since they had variable duration of treatments based on response to initial treatment, also associated with high standard errors and wide CrI, leading to problems with convergence of the model when included). There were 34 two-arm and three three-arm trials. Table [2](#Tab2){ref-type="table"} shows only the significant odds ratios, relative risk and risk differences only, and an additional file shows all comparisons in more detail (see Additional file [5](#MOESM5){ref-type="media"}). CYC, MMF, CSA, and TAC were superior to corticosteroids alone in achieving renal remission/response (Table [2](#Tab2){ref-type="table"}). CYC low dose (LD) was less likely than MMF, TAC, CSA, and CYC and CYC HD less likely than MMF and CSA to achieve renal remission/response. CSA was more likely than plasmapharesis and azathioprine to achieve renal remission/response (Table [2](#Tab2){ref-type="table"}). The quality of evidence was rated as moderate (downgraded for imprecision). Absolute event rates ranged from 28 to 75 % and are shown in more detail in an additional file (see Additional file [6](#MOESM6){ref-type="media"}).Table 2Significant differences^a^ between treatments of lupus nephritis for a composite end-point of renal remission or renal response (includes partial remission, complete remission and renal response)TreatmentReferenceOdds ratio (95 % CrI)Relative risk (95 % CrI)Risk difference % (95 % Crl)CYCPRED*2.35 (1.28, 4.23)1.60 (1.60, 2.24)0.21 (0.06, 0.34)*MMF*3.26 (1.57, 6.72)1.82 (1.82, 2.60)0.28 (0.11, 0.44)*TAC*2.51 (1.11, 5.76)1.64 (1.64, 2.44)0.22 (0.03, 0.41)*CSA*5.69 (2.02, 17.61)2.15 (2.15, 3.18)0.40 (0.17, 0.58)*CYC LDCYC*0.32 (0.10, 0.89)0.51 (0.51, 0.95)−0.26 (−0.45, −0.03)*CYC LDMMF*0.23 (0.08, 0.61)0.45 (0.45, 0.81)−0.34 (−0.53, −0.12)*CYC HD*0.40 (0.20, 0.74)0.65 (0.65, 0.89)−0.22 (−0.38, −0.07)*CSAAZA*3.20 (1.04, 10.19)1.53 (1.53, 2.39)0.26 (0.01, 0.47)*CYC LDTAC*0.30 (0.09, 0.91)0.50 (0.50, 0.95)−0.28 (−0.50, −0.02)*PLASMACSA*0.19 (0.04, 0.92)0.49 (0.49, 0.97)−0.38 (−0.66, −0.02)*CYC LD*0.13 (0.03, 0.52)0.38 (0.38, 0.76)−0.45 (−0.69, −0.15)*CYC HD*0.23 (0.06, 0.72)0.55 (0.55, 0.87)−0.33 (−0.57, −0.08)*CYC HD*0.23 (0.06, 0.72)0.55 (0.55, 0.87)−0.33 (−0.57, −0.08)*Random-effects modelResidual deviance82.2 vs. 77 data pointsDeviance information criteria389.332Fixed-effects modelResidual Deviance88.8 vs. 77 data pointsDeviance information criteria390.488Based on 37 RCTs with 2697 patients: 35 two-arm trials and three three-arm trials^a^For all comparisons of treatments of lupus nephritis for renal remission/response please see Appendix 5For absolute rates for events used for calculation of risk difference, please see Appendix 6*OR* odds ratio, *RR* relative risk, *RD* risk difference, *CrI* credible interval, *CYC* cyclophosphamide, *MMF* mycophenolate mofetil, *CSA* cyclosporine, *TAC* tacrolimus, *LEF* leflunomide, *PRED* prednisone, prednisolone or methylprednisolone, *AZA* azathioprine, *RTX* rituximab, *HD* high dose, *LD* low dose, when not specified, it indicates standard doseSignificant odds ratios are in italicsThe odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients

Treatment failure: renal relapse/renal flare {#Sec8}
--------------------------------------------

Thirteen studies with 1,108 patients provided data; 11 were two-arm and two were three-arm studies. MMF and CYC were associated with a lower rate of renal relapse/flare compared to PRED and MMF was associated with a lower rate of renal relapse/flare than AZA (Table [3](#Tab3){ref-type="table"}). The quality of evidence was rated as moderate (downgraded for imprecision). The event rates ranged from 14 to 49 % and are shown in more detail in an additional file (see Additional file [6](#MOESM6){ref-type="media"}).Table 3Comparison of all lupus nephritis treatments for a composite of renal relapse or renal flareTreatmentReferenceOdds ratio (95 % CrI)Relative risk (95 % CrI)Risk difference % (95 % Crl)AZAPRED0.33 (0.08, 1.23)0.50 (0.17, 1.12)−0.24 (−0.47, 0.05)MMF*0.17 (0.04, 0.67)0.29 (0.09, 0.78)*−*0.34 (*−*0.53,* −*0.09)*CYC*0.18 (0.05, 0.58)0.31 (0.11, 0.71)*−*0.33 (*−*0.51,* −*0.12)*CSA0.24 (0.03, 1.60)0.39 (0.07, 1.26)−0.29 (−0.52, 0.11)CYC + AZA0.32 (0.05, 1.67)0.48 (0.10, 1.29)−0.25 (−0.50, 0.12)MMF-AZA0.41 (0.03, 5.46)0.58 (0.07, 1.83)−0.20 (−0.51, 0.36)MMFAZA*0.51 (0.32, 0.87)0.59 (0.38, 0.90)*−*0.10 (*−*0.20,* −*0.02)*CYC0.55 (0.24, 1.26)0.62 (0.32, 1.21)−0.09 (−0.26 0.03)CSA0.74 (0.18, 2.95)0.80 (0.23, 2.01)−0.04 (−0.23, 0.23)CYC + AZA0.95 (0.27, 3.09)0.96 (0.34, 2.11)−0.01 (−0.19, 0.24)MMF-AZA1.23 (0.14, 12.15)1.16 (0.19, 3.76)0.04 (−0.25, 0.53)CYCMMF1.06 (0.44, 2.58)1.05 (0.51, 2.29)0.01 (−0.13, 0.12)CSA1.43 (0.32, 6.17)1.33 (0.36, 3.81)0.04 (−0.12, 0.35)CYC + AZA1.84 (0.51, 6.00)1.62 (0.56, 3.85)0.08 (−0.07, 0.35)MMF-AZA2.39 (0.27, 23.30)1.94 (0.31, 6.94)0.13 (−0.12, 0.63)CSACYC1.35 (0.27, 6.52)1.27 (0.31, 3.86)0.04 (−0.14, 0.37)CYC + AZA1.72 (0.44, 6.37)1.53 (0.49, 3.83)0.08 (−0.09, 0.3)MMF-AZA2.24 (0.24, 23.15)1.85 (0.28, 6.46)0.13 (−0.13, 0.63)CYC + AZACSA1.27 (0.20, 8.09)1.20 (0.30, 5.35)0.03 (−0.29, 0.35)MMF-AZA1.67 (0.13, 25.89)1.43 (0.19, 8.68)0.08 (−0.31, 0.62)MMF-AZACYC + AZA1.30 (0.22, 9.13)1.20 (0.28, 3.68)0.04 (−0.01, 0.46)Random-effects modelResidual deviance32.06 vs. 28 data pointsDeviance information criteria146.869Fixed-effects modelResidual deviance34.31 vs. 28 data pointsDeviance information criteria147.018Based on 13 RCTs with 1108 patients: 11 two-arm trials and two three-arm trialsSignificant odds ratios are in italicsFor absolute rates for events used for calculation of risk difference, please see Appendix 6*OR* odds ratio, *RR* relative risk, *RD* risk difference, *CrI* credible interval, *CYC* cyclophosphamide, M*MF* mycophenolate mofetil, *CSA* cyclosporine, *TAC* tacrolimus, L*EF* leflunomide, *PRED* prednisone, prednisolone or methylprednisolone, *AZA* azathioprine, *RTX* rituximabCYC + AZA CYC with AZA, MMF-AZA MMF followed by AZAMerged doses for PRED and CYC and comparing only between treatments. We did not lose any study, but it is a limitation of this analysis

Amenorrhea/ovarian failure {#Sec9}
--------------------------

Eight RCTs with 839 patients provided data; seven were two-arm and one trial was a three-arm trial. CYC was more likely than MMF and PRED to be associated with amenorrhea/ovarian failure (Table [4](#Tab4){ref-type="table"}). CYC LD was associated with higher risk of amenorrhea/ovarian failure than MMF. The quality of evidence was rated as moderate (downgraded for imprecision). Absolute event rates ranged from 8 to 61 % and are shown in more detail in an additional file (see Additional file [6](#MOESM6){ref-type="media"}).Table 4Comparison of all lupus nephritis treatments for fertility issues (amenorrhea or ovarian failure)TreatmentReferenceOR (95 % CrI)RR (95 % CrI)RD % (95 % Crl)CYCPRED*3.81 (1.26, 14.31)2.64 (1.18, 7.51)0.25 (0.04, 0.47)*MMF0.48 (0.09, 3.04)0.52 (0.11, 2.58)−0.07 (−0.23, 0.13)AZA2.74 (0.26, 28.27)2.12 (0.30, 8.18)0.17 (−0.15, 0.65)CYC LD9.06 (0.63, 121.50)3.79 (0.68, 11.71)0.45 (−0.06, 0.81)MMFCYC*0.13 (0.03, 0.41)0.20 (0.05, 0.56)*−*0.31 (*−*0.47,* −*0.16)*AZA0.69 (0.09, 5.08)0.79 (0.14, 1.95)−0.08 (−0.37, 0.36)CYC LD2.23 (0.23, 23.20)1.46 (0.34, 2.71)0.19 (−0.27, 0.55)AZAMMF5.25 (0.78, 54.39)3.68 (0.81, 19.08)0.22 (−0.02, 0.68)CYC LD*16.35 (1.97, 247.70)6.49 (1.72, 30.95)0.50 (0.06, 0.87)*CYC LDAZA3.20 (0.55, 21.24)1.69 (0.68, 6.12)0.22 (−0.11, 0.60)Random-effects modelResidual deviance15.93 vs. 17 data pointsDeviance information criteria72.233Fixed-effects modelResidual deviance16.16 vs. 17 data pointsDeviance information criteria72.069Based on eight RCTs with 839 patients: seven two-arm trials and one three-arm trialSignificant odds ratios are in italicsFor absolute rates for events used for calculation of risk difference, please see Appendix 6*OR* odds ratio, *RR* relative risk, *RD* risk difference, *CrI* credible interval, *HD* high dose, *LD* low dose; when not specified, it indicates standard dose, *CYC* cyclophosphamide, *MMF* mycophenolate mofetil, *CSA* cyclosporine, *TAC* tacrolimus, *LEF* leflunomide, *PRED* prednisone, prednisolone or methylprednisolone, *AZA* azathioprine, *RTX* rituximabThe odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients

Bone marrow toxicity: cytopenia (including leucopenia) {#Sec10}
------------------------------------------------------

Sixteen trials provided data on 2257 patients: 15 were two-arm and one was a three-arm trial. Compared to MMF, several immunosuppressive drugs were associated with a higher risk of cytopenia: CYC, AZA, CYC LD, and CYC HD (Table [5](#Tab5){ref-type="table"}). The quality of evidence was rated as moderate (downgraded for imprecision). Absolute event rates ranged from 7 to 30 % and are shown in more detail in an additional file (see Additional file [6](#MOESM6){ref-type="media"}).Table 5Comparison of all lupus nephritis treatments for bone marrow toxicity (cytopenia including leucopenia)TreatmentReferenceOR (95 % CrI)RR (95 % CrI)RD % (95 % Crl)CYC SDMMF*2.16 (1.14, 4.03)1.99 (1.13, 3.37)0.07 (0.01, 0.16)*AZA SD*2.42 (1.01, 7.07)2.19 (1.01, 5.06)0.09 (0.00, 0.27)*CYC LD*5.31 (1.26, 24.65)4.03 (1.23, 10.11)0.22 (0.02, 0.56)*CYC HD*5.36 (1.95, 18.08)4.06 (1.81, 8.96)0.22 (0.07, 0.48)*RTX + MMF SD3.50 (0.61, 23.14)2.95 (0.63, 9.43)0.14 (−0.03, 0.56)AZA SDCYC SD1.11 (0.39, 4.03)1.09 (0.44, 3.07)0.01 (−0.11, 0.22)CYC LD2.45 (0.51, 13.07)2.01 (0.56, 5.91)0.15 (−0.08, 0.50)CYC HD2.47 (0.77, 9.99)2.03 (0.80, 5.38)0.15 (−0.04, 0.43)RTX + MMF SD1.63 (0.26, 11.77)1.49 (0.30, 5.31)0.07 (−0.13, 0.49)CYC LDAZA SD2.16 (0.42, 10.83)1.80 (0.49, 5.39)0.13 (−0.12, 0.47)CYC HD2.20 (0.56, 8.96)1.83 (0.65, 5.16)0.13 (−0.10, 0.40)RTX + MMF SD1.43 (0.18, 11.42)1.33 (0.23, 5.33)0.05 (−0.21, 0.48)CYC HDCYC LD1.01 (0.29, 3.75)1.01 (0.46, 2.74)0.00 (−0.28, 0.24)RTX + MMF SD0.66 (0.06, 7.15)0.74 (0.12, 3.78)−0.07 (−0.48, 0.40)RTX + MMF SDCYC HD0.65 (0.08, 5.36)0.73 (0.13, 2.81)−0.08 (−0.41, 0.37)Random-effects modelResidual deviance31.43 vs. 33 data pointsDeviance information criteria165.076Fixed-effects modelResidual deviance38.78 vs. 33 data pointsDeviance information criteria167.984Based on 16 RCTs with 2257 patients: 15 two-arm trials and one three-arm trialSignificant odds ratios are in italicsFor absolute rates for events used for calculation of risk difference, please see Appendix 6*OR* odds ratio, *RR* relative risk, *RD* risk difference, *CrI* credible interval, *HD* high dose, *LD* low dose; when not specified, it indicates standard dose, *CYC* cyclophosphamide, *MMF* mycophenolate mofetil, *CSA* cyclosporine, *TAC* tacrolimus, *LEF* leflunomide, *PRED* prednisone, prednisolone or methylprednisolone, *AZA* azathioprine, *RTX* rituximabMMF-AZA, MMF followed by AZARTX + MMF, RTX combined with MMFEstimates for LEF HD were obtained from data from only one study and were therefore impreciseThe odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients

Sensitivity analyses limited to partial or complete renal remission only {#Sec11}
------------------------------------------------------------------------

An additional file shows in detail the odds ratios for comparisons of immunosuppressive drugs and corticosteroids in lupus nephritis for partial/complete remission, a sensitivity analysis (renal response excluded from the composite outcome; see Additional file [7](#MOESM7){ref-type="media"}). Results were similar to the main analyses, with minor exceptions. Thus, most observations from the main analysis were confirmed in this sensitivity analysis.

Rankograms and staircase diagrams {#Sec12}
---------------------------------

Figure [2](#Fig2){ref-type="fig"} shows the Rankograms for various treatments for the outcomes of interest. Among the top ranked were CSA for renal remission/response, prednisone for renal relapse/flare, CYC for ovarian failure/amenorrhea and CYC for bone marrow toxicity (Fig. [3](#Fig3){ref-type="fig"}). An additional file shows in detail comparisons of various treatments to each other for each outcome, another way to visualize the key comparisons between treatments (see Additional file [8](#MOESM8){ref-type="media"}).Fig. 3Rankograms for composite study outcomes in lupus nephritis, renal remission or renal response (**a**), renal relapse or renal flare (**b**), fertility issues (**c**), and bone marrow toxicity (**d**). Legend: This two-dimensional plot show on the *x*-axis (*horizontal*) the possible ranks of the treatment from best to the last ranks and on the *y*-axis (*vertical*) the probability of each of the treatments to assume those possible ranks for each outcome. For example, for renal relapse/flare (an undesired outcome), the highest probability was evident with corticosteroids alone, followed by MMF-AZA, followed by AZA and others

Discussion {#Sec13}
==========

In this systematic review and NMA of outcomes in patients with lupus nephritis, we made several important observations. Results of this study are of great value to both medical and patient communities, given the growing and renewed focus on patient-centered education and outcomes. We directly compared benefits and risks of medications that are used to treat SLE nephritis. The information presented here served as the foundation for a decision-aid tool that can be easily understood that is being tested in a randomized trial, currently underway. Given the novel NMA methodology and our ability to perform indirect comparisons using the NMA, several of our findings are new and merit further discussion.

We noted differences between immunosuppressive drugs regarding renal remission/response. Interestingly, high-dose CYC was significantly less effective than MMF in leading to renal remission/response with a relative risk of 0.65 and an odds ratio of 0.40. This is an interesting finding and is consistent with the trial data from Ginzler et al. that found that MMF was superior to IV CYC in inducing complete renal remission \[[@CR37]\].

We also found that CYC LD (which includes EURO-lupus regimen) was inferior to MMF, CSA and CYC standard dose for renal remission/response. We realize that not all trials are same; however, the superiority of these commonly used immunosuppressive drugs to CYC LD is worth some discussion. This benefit of using low-dose CYC must be weighed against the potential harms of using MMF, CSA or CYC standard dose in a patient with lupus nephritis. Several other differences we noted might be of interest to clinicians and patients when making treatment decisions for lupus nephritis.

We confirmed that immunosuppressive drugs were more effective than corticosteroids alone (most often prednisone or prednisolone) for renal remission/response by two to four times, that is, CYC, MMF, CSA, and tacrolimus led to renal remission significantly more often than corticosteroids alone. The lower risk of renal relapse or flare with MMF and CYC compared to corticosteroids alone is also supportive of this finding and not surprising. Other immunosuppressives (AZA, CSA, CYC-AZA, MMF-AZA) also seemed to be possibly more effective than corticosteroids alone for preventing renal relapse/flare, but did not reach significance.

Significant differences were found in the risk of amenorrhea/ovarian failure (fertility issues). These are important findings, since a disproportionate number of young women are affected by lupus. An increased risk of amenorrhea/ovarian failure was seen with CYC compared to MMF and PRED, which confirms a long-known clinical observation, but now provides estimates of the comparative risk. Ovarian failure is an important discussion point during lupus treatment decision-making in young women, especially when the use of CYC is considered.

We found that CYC SD, CYC LD, CYC HD, and AZA had two to five times higher risk of cytopenia than MMF. Our comprehensive NMA provided a robust treatment estimates for these comparisons that can be shared with patients in a more understandable format at the time of treatment decision-making for lupus nephritis in regular clinical care.

Our study has several limitations. Meta-analyses are observational studies and therefore can have limitations of any observational study. Heterogeneity is an issue with all meta-analyses, including NMA. We assessed for clinical heterogeneity of studies prior to conducting the analyses, with the help of two clinicians (including a rheumatologist and a lupus expert) who assessed for systematic differences between study populations and disease stage by medications regimens. We noted some clinical heterogeneity between trials, but did not find major systematic differences by the type of medication used. We acknowledge that no two clinical trials are alike. This applies to our NMA as well, and therefore, the results should be interpreted with some caution. Another study limitation may be that we searched two databases.

The NMA incorporates both direct and indirect comparisons. As can be seen from the network diagrams for these analyses, for some outcomes assessed in this study, direct comparisons were fewer, which indicates that most evidence came from indirect comparisons; addition of data from direct comparator trials in future NMA would increase the confidence in these findings. Due to multiple NMA comparisons performed, some findings may be resulting from chance. However, we think that type II error, i.e., missing important differences due to small sample size, is a bigger concern, since most included trials for this rare condition, were of small size. For comparisons with large relative effects (odds or risk ratios), one should keep in mind the underlying rates, which varied between outcomes and were very low for some composite outcomes. In these cases, the absolute difference between treatments is still small, even though relative effect may be five or ten times, or 0.05 times. Comparisons with wider confidence intervals must be interpreted with caution, since these indicate small study numbers, or a lower confidence in the certainty of the estimate. It is possible (and even likely sometimes) that addition of more data from studies in the future may change these estimates.

Conclusions {#Sec14}
===========

This systematic review and NMA provides the most current, comprehensive comparison of immunosuppressive medications and corticosteroids used to treat lupus nephritis. These findings must be interpreted considering between study heterogeneity. This comparative effectiveness research provides estimates of key benefits and harms that would be of interest to both physicians and their patients. The state-of-the-art methodology used here should be duplicated for other diseases where physicians and patients will benefit from comparisons of commonly used treatments.
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Additional file 1:Detailed definitions of efficacy outcomes and medication doses. (DOCX 22 kb)Additional file 2:A. PubMed search strategy for updating the American College of Rheumatology (ACR) lupus treatment guideline and the Cochrane library searches. B. Second Search strategy to identify any lupus trial for side effects of medications in PubMed and Scopus databases (data abstracted, but not used due to scant data and the possibility of heterogeneity in patient population, i.e., lupus nephritis vs. lupus with all other manifestations). (DOC 25 kb)Additional file 3:PRISMA NMA checklist of items to include when reporting a systematic review involving a network meta-analysis. (DOCX 97 kb)Additional file 4:Characteristics of included studies. (DOCX 41 kb)Additional file 5:All Comparisons of various treatments for the composite end-point of renal remission or renal response (includes partial remission/complete remission/renal response). (DOCX 28 kb)Additional file 6:Event rates for the outcomes of interest. (DOCX 19 kb)Additional file 7:Sensitivity analysis including partial/complete renal remission only. (DOCX 29 kb)Additional file 8:Staircase diagrams for key outcomes. (DOCX 26 kb)

NMA

:   Network meta-analysis

OR

:   Odds ratio

CrI

:   Credible interval

MTC

:   Mixed treatment comparison

AHRQ

:   Agency for Healthcare Research and Quality

UAB

:   University of Alabama at Birmingham

RCTs

:   Randomized controlled trials

CCTs

:   Controlled clinical trials
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